PRESS RELEASE published on 06/26/2024 at 07:30, 1 year 7 months ago Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study Crossject provides insights on ZEPIZURE® potential in light of RAMPART and its bioequivalence study. IM midazolam favored over IV lorazepam for emergency epilepsy management Crossject ZEPIZURE RAMPART Study Bioequivalence Study Emergency Epilepsy Management
BRIEF published on 06/18/2024 at 12:35, 1 year 8 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Droits De Vote Capital Social AMF Pharmacie Spécialisée Crossject
BRIEF published on 06/18/2024 at 12:35, 1 year 8 months ago Crossject: Information relating to the total number of voting rights and shares making up the share capital Share Capital Voting Rights AMF Crossject Specialized Pharmacy
PRESS RELEASE published on 06/18/2024 at 12:30, 1 year 8 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Publication du nombre total de droits de vote et d'actions de CROSSJECT au 31 mai 2024 conformément aux réglementations. Détails sur le capital social Droits De Vote Capital Social AMF Crossject Pharma
BRIEF published on 06/13/2024 at 09:41, 1 year 8 months ago Crossject : Information sur le nombre de droits de vote et d'actions Droits De Vote Capital Social Actions 2024 Crossject
BRIEF published on 06/13/2024 at 09:41, 1 year 8 months ago Crossject: Information on the number of voting rights and shares Share Capital Voting Rights Actions 2024 Crossject
PRESS RELEASE published on 06/13/2024 at 09:36, 1 year 8 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Crossject publie le nombre total de droits de vote et d'actions au 31 mai 2024 conformément aux normes réglementaires Droits De Vote Capital Social Actions Crossject Pharma
BRIEF published on 06/12/2024 at 07:35, 1 year 8 months ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Crossject ZEPIZURE® Dan Chiche Directeur Médical
BRIEF published on 06/12/2024 at 07:35, 1 year 8 months ago Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer Crossject ZEPIZURE® Dan Chiche Medical Director
PRESS RELEASE published on 06/12/2024 at 07:30, 1 year 8 months ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Nomination de Dan Chiche, MD en tant que Directeur Médical Amérique du Nord chez Crossject, renforçant l'équipe dirigeante et la présence aux États-Unis pour lancer ZEPIZURE en 2025 Amérique Du Nord Crossject ZEPIZURE Dan Chiche Directeur Médical
Published on 02/20/2026 at 20:15, 1 hour 25 minutes ago Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 1 hour 25 minutes ago Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 3 hours 10 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 5 hours 55 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 7 hours 10 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 18:36, 3 hours 3 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 3 hours 8 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 3 hours 39 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 3 hours 39 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 19:29, 2 hours 10 minutes ago SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 2 hours 10 minutes ago SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 3 hours 40 minutes ago TERACT - Résiliation du contrat de liquidité
